Diseases [C] » Neoplasms [C04] » Precancerous Conditions » Preleukemia
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Preleukemia
Description
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria. MeSH
Hierarchy View
Phase 2 Indicated Drugs (1)
Phase 1 Indicated Drugs (5)
Organization Involved with Phase 4 Indications (23)
Organization Involved with Phase 3 Indications (96)
Albert Einstein Israelite Hospital
ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
Blood and Marrow Transplant Clinical Trials Network
Cancer and Leukemia Group B (CALGB)
Center for International Blood and Marrow Transplant Research
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
European Organisation for Research and Treatment of Cancer
European Working Group of MDS in Childhood
Fondazione Italiana Diabete Onlus
Groupe Francophone des Myelodysplasies
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Oregon Health and Science University
Shanghai 6th People's Hospital
Shanghai institute of Hematology
Shanghai Ruijin Hospital North
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Dresden
Organization Involved with Phase 2 Indications (225)
Asociación Andaluza de Hematología y Hemoterapia
Azienda Ospedaliera Antonio Cardarelli
Bambino Gesù Hospital and Research Institute
BioMed Valley Discoveries, Inc
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Case Western Reserve University
Cell Therapy Transplant Canada
Chao Family Comprehensive Cancer Center
City of Hope National Medical Center
Ciusss de L'Est de l'Île de Montréal
Cyclacel Pharmaceuticals, Inc.
Department of Health and Human Services
Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Herbert Irving Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Hoosier Cancer Research Network
Inner Mongolia International Mongolian Hospital
Korea Research Institute of Bioscience & Biotechnology
Lixte Biotechnology Holdings, Inc.
Louis A. Weiss Memorial Hospital
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
National Cancer Institute, France
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
North Central Cancer Treatment Group
Our Lady of Mercy Medical Center
Pavlov First Saint Petersburg State Medical University
QOL-ONE Associazione Culturale e di Ricerca
Royal Marsden Hospital NHS Trust
Sclnow Biotechnology Co., Ltd.
Universita' Cattolica del Sacro Cuore
Université catholique de Louvain
University Hospital of Mont-Godinne
University of Alabama, Birmingham
University of California, Davis
University of California, Irvine
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern California
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (81)
Alex's Lemonade Stand Foundation
American Society for Blood and Marrow Transplantation
Chinese Academy of Medical Sciences
CLL Global Research Foundation
Damon Runyon Cancer Research Foundation
HonorHealth Research Institute
Icahn School of Medicine at Mount Sinai
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National University of Singapore
Organization Involved with Other Experimental Indications (10)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
